Extending Therapy Options in Treating Lipid DisordersA Clinical Review of Cerivastatin, a Novel HMG-CoA Reductase Inhibitor

被引：0
|
作者：
Evan A. Stein
机构：
[1] Medical Research Laboratories,
来源：
Drugs | 1998年 / 56卷
关键词：
Adis International Limited; Pravastatin; Lovastatin; Fluvastatin; Cerivastatin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Cerivastatin is a third generation pure enantiomeric HMG-CoA reductase inhibitor. It reduces low density lipoprotein (LDL)-cholesterol by 22 to 44% at doses of 0.1 to 0.8 mg/day The drug has been extensively evaluated for more than 5 years in clinical trials and is currently marketed in a number of countries at doses of 0.1 to 0.3 mg/day.
引用
收藏
页码：25 / 31
页数：6
相关论文
共 50 条
12345